A Phase 2a Trial of Brepocitinib for Cicatricial Alopecia

    Eden David, Neda Shokrian, Ester Del Duca, Marguerite Meariman, Celina Dubin, Kelly Hawkins, Elizabeth Andrews, Savina Sikand, Giselle Singer, Barry S. Oemar, Yeriel Estrada, Swaroop Bose, Juliana Pulsinelli, Ping Mahling, Joel Corrêa da Rosa, Benjamin Ungar, Elena Peeva, Emma Guttman‐Yassky
    TLDR Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
    The phase 2a trial of brepocitinib for cicatricial alopecia demonstrated that the drug significantly reduces CCL5 expression and was well tolerated by participants at week 24, successfully meeting the coprimary endpoints. The study found that brepocitinib effectively reduces inflammatory biomarker expression and improves clinical severity in patients, all while maintaining a favorable safety profile.
    Discuss this study in the Community →

    Research cited in this study

    14 / 14 results

    Related Community Posts Join

    0 / 0 results
    — no results

    Similar Research

    5 / 84 results